TYRA

$37.92

Post-MarketAs of Mar 17, 8:00 PM UTC

Tyra Biosciences, Inc., a clinical-stage biotechnology company, develops precision medicines for fibroblast growth factor receptor (FGFR) biology in the United States.

OverviewIntradayAnalysisPROIntelligencePROAsk AIPRO

Historical Price

Price (Line)
50-Day SMA
200-Day SMA
Synthesizing Whystock Narrative...
Loading Financials...

Peer Comparison

JNJUNHPFE

Whystock Valuation Model

Calculated using a trailing P/E relative model adjusted by sector ROE and historical growth.
Current Price$37.92
Potential Upside
5%
Whystock Fair Value$39.82
Price
UndervaluedFair ValueOvervalued

Fundamentals

SectorHealthcare
IndustryBiotechnology

Tyra Biosciences, Inc., a clinical-stage biotechnology company, develops precision medicines for fibroblast growth factor receptor (FGFR) biology in the United States. The company offers SNĂ…P, a precision medicine platform that enables drug design th...

Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$2.04B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
1.06
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROIC
Average efficiency. Growth may require heavy reinvestment.
-39.83%
Quick Ratio
Pristine liquidity. Sufficient cash to cover all near-term obligations.
14.25

Recent News

Simply Wall St.
Mar 4, 2026

Did Deeper Losses and Dabogratinib Progress Just Shift Tyra Biosciences' (TYRA) Investment Narrative?

Tyra Biosciences reported a higher net loss for the fourth quarter and full year 2025, while simultaneously advancing its dabogratinib 3x3 clinical strategy and bolstering its leadership team. This combination of deeper losses and intensified late-stage development around dabogratinib in FGFR3-driven diseases is sharpening investor focus on the company’s precision oncology and rare disease ambitions. We will now examine how Tyra’s dabogratinib 3x3 strategy and recent clinical progress shape...

BEARISH
Negative press. News cycle fixated on risk factors or misses.
MarketBeat
Mar 2, 2026

Tyra Biosciences Narrows Dabogratinib Focus, Teases Mid-Year NMIBC and 2H Achondroplasia Data

Tyra Biosciences (NASDAQ:TYRA) CEO Todd Harris said the company has narrowed its focus to what he described as the “highest value opportunities” for its selective FGFR3 inhibitor dabogratinib, emphasizing indications where FGFR3 alterations are clear drivers of disease. Speaking at a virtual confer

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.
Motley Fool
Feb 23, 2026

From Sizable Stake to Zero: The Likely Reason Why Agios Shares Lost a $94 Million Backer

Agios Pharmaceuticals develops therapies for rare blood disorders, anchored by its PYRUKYND franchise and early-stage clinical programs.

NEUTRAL
Neutral flow. Standard news cycle with no clear sentiment tilt.
Motley Fool
Feb 23, 2026

Viridian Therapeutics Stock Up 75%, but One Fund Just Sold Off Its $69 Million Stake

Viridian Therapeutics develops monoclonal antibody therapies targeting rare diseases, with a focus on thyroid eye disease treatments.

NEUTRAL
Neutral flow. Standard news cycle with no clear sentiment tilt.
Motley Fool
Feb 23, 2026

Spyre Therapeutics Stock Surges This Past Year as $10.5 Million Buy Lifts Stake to $78 Million

Spyre Therapeutics develops preclinical monoclonal antibody therapies targeting inflammatory bowel disease and related conditions.

NEUTRAL
Neutral flow. Standard news cycle with no clear sentiment tilt.